AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion

Taking stock of the drug industry, from the lab to the medicine chest

August 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kristoffer Tripplaar/Sipa/AP STAT+ | AbbVie to buy Gilgamesh's psychedelic drug for up to $1.2 billion The pharma giant will acquire the treatment, called bretisilocin, for up to $1.2 billion, including an upfront payment and development milestones. By Elaine Chen STAT+ | Amid cries for retraction, a medical journal reviews a discredited, 24-year-old paper on an antidepressant The move comes after an attorney filed a lawsuit saying the journal and its publisher violated Washington, D.C., consumer protection laws. By Ed Silverman STAT+ | Opinion: The future of medicine lies in multifunctional therapies The shift to multifunctional therapies marks a turning point in terms of how we conceptualize, design, and develop medicines. By Sasha Ebrahimi and Milan Mrksich

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser